Unigene and Tarix report highly increased oral bioavailability of 'Peptelligence-engineered' TXA127

USA-based Unigene Laboratories Laboratories (OTCBB: UGNE) and Tarix Pharmaceuticals yesterday announced the successful completion of a feasibility study of an oral formulation of TXA127, Tarix' lead peptide drug candidate.

Data from the feasibility study demonstrated that the oral formulation of TXA127 produced extremely high exposure in the blood that resulted in a several-fold increase in bioavailability as compared to the oral delivery of the unformulated drug, and was equal to or greater than that achieved by the current subcutaneous formulation.

The oral formulation, developed jointly by Unigene and Tarix under a previously agreed feasibility program, leverages Unigene's Peptelligence technology platform to enable enhanced oral delivery of TXA127. Tarix is developing TXA127 for multiple therapeutic indications, including enhancement of engraftment following peripheral blood and cord blood stem cell transplantation, reduction in GVHD and mucositis following allogeneic stem cell transplantation, and peripheral vascular disease.